调控人血小板生成素受体构象可将JAK2 V617F驱动的激活与细胞因子诱导的刺激解偶联
本研究系统表征了生理与病理条件下人血小板生成素受体(hTpoR)的激活,发现Tpo诱导与JAK2 V617F介导的激活对应不同的二聚体构象,特定点突变可选择性抑制JAK2 V617F驱动的激活而不影响Tpo诱导的信号,提示调控hTpoR构象是JAK2 V617F阳性骨髓增殖性肿瘤的可行治疗策略。
要点
- hTpoR在Tpo诱导与JAK2 V617F介导激活下 adopts 不同二聚体构象
- 鉴定出参与JAK2 V617F特异性激活的hTpoR氨基酸及特定二聚体构象
- 调控hTpoR构象可特异性抑制JAK2 V617F驱动激活而不影响Tpo信号
核心结论
- 调控人血小板生成素受体构象是JAK2 V617F阳性骨髓增殖性肿瘤的可行治疗策略。
- 研究结果为基于hTpoR精确残基的新型药物开发奠定了基础。
研究设计与样本
- 研究采用hTpoR跨膜域和胞质域受控二聚化系统。
- 在造血细胞系和原代骨髓细胞中全长受体背景下验证了发现。
主要发现
- Tpo诱导与JAK2 V617F介导激活下hTpoR adopts 不同二聚体构象。
- 点突变调控hTpoR构象可特异性抑制JAK2 V617F驱动激活而不影响Tpo诱导信号。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The thrombopoietin receptor (TpoR) plays a central role in myeloproliferative neoplasms (MPNs). Mutations in JAK2, calreticulin, or TpoR itself drive the constitutive activation of TpoR and uncontrolled proliferation and differentiation of hematopoietic stem cells and progenitors. The JAK2 V617F mutation is responsible for most MPNs, and all driver mutants induce pathologic TpoR activation. Existing therapeutic strategies have focused on JAK2 kinase inhibitors that are unable to differentiate between the mutated MPN clone and healthy cells. Surprisingly, the targeting of TpoR itself has remained poorly explored despite its central role in pathology. Here, we performed a comprehensive characterization of human TpoR activation under physiological and pathological conditions, focusing on the JAK2 V617F mutant. Using a system of controlled dimerization of the transmembrane and cytosolic domains of TpoR, we discovered that human TpoR (hTpoR) adopts different dimeric conformations upon Tpo-induced vs JAK2 V617F-mediated activation. We identified the amino acids and specific dimeric conformation of hTpoR responsible for activation in complex with JAK2 V617F and confirmed our findings in the full-length receptor context in hematopoietic cell lines and primary bone marrow cells. Remarkably, we found that the modulation of hTpoR conformations by point mutations allowed for specific inhibition of JAK2 V617F-driven activation without affecting Tpo-induced signaling. Our results demonstrate that modulation of the hTpoR conformation is a viable therapeutic strategy for JAK2 V617F-positive MPNs and set the path for novel drug development by identifying precise residues of hTpoR involved in JAK2 V617F-specific activation.
引用
- Papadopoulos N, Pristavec A, Nédélec A, et al. Modulation of human thrombopoietin receptor conformations uncouples JAK2 V617F-driven activation from cytokine-induced stimulation. Blood. 2023. PMID: 37616564. doi:10.1182/blood.2022019580
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。